Search

#Biotechnology
The New York Times @nytimes.com Β· New York City πŸ‡ΊπŸ‡Έ Β· 2d

Scientists at Bristol Myers Squibb's Devens facility are utilizing artificial intelligence to monitor critical variables in the production of disease-fighting proteins, enhancing drug manufacturing efficiency by 40% and tackling shortages, while the company faces tough competition from China's rapidly advancing biotech sector and implements cost-cutting measures in light of patent expirations and the potential impact of AI on jobs in the industry. #ArtificialIntelligence #PharmaceuticalInnovation #Biotechnology #US #CN #TH

www.nytimes.com
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
In a sterile Bristol Myers Squibb lab about an hour north of Boston, scientists in scrubs and hairnets transfer living cells to a 2,000-liter stainless steel bioreactor that grows them for weeks.
The New York Times @nytimes.com Β· New York City πŸ‡ΊπŸ‡Έ Β· 2d

At the Bristol Myers Squibb facility in Devens, Massachusetts, scientists are leveraging artificial intelligence to enhance the production of genetically engineered proteins for disease treatment, improving drug output by 40% and allowing real-time intervention during the manufacturing process, while facing challenges in translating technological advancements into broader productivity gains compared to China's rapidly scaling biotech sector. #ArtificialIntelligence #Biotechnology #DrugDiscovery #US #CN #TH

www.nytimes.com
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception.
In a sterile Bristol Myers Squibb lab about an hour north of Boston, scientists in scrubs and hairnets transfer living cells to a 2,000-liter stainless steel bioreactor that grows them for weeks.
Euronews English @euronews.com Β· Lyon πŸ‡«πŸ‡· Β· 4d

Mark Zuckerberg and Priscilla Chan's Biohub is investing $500 million in a five-year initiative to create AI models of human cells, aiming to revolutionize disease research and treatment through open-access data while facing challenges in data scale and accuracy. #ArtificialIntelligence #Biotechnology #HealthInnovations #US #FR #DE #CN #JP #GB #IN

www.euronews.com
Can AI simulate human cells? Inside Mark Zuckerberg's plan
Mark Zuckerberg and Priscilla Chan's Biohub is investing $500 million to build AI models of human cells, as tech giants race to bring artificial intelligence into biology.